Differential Expression of BDNF and BIM in Streptozotocin-induced Diabetic Rat Retina After Fluoxetine Injection

In Vivo. 2021 May-Jun;35(3):1461-1466. doi: 10.21873/invivo.12398.

Abstract

Background: Chronic diabetic retinopathy (DR) is a diabetic complication that causes blindness. Brain-derived neurotrophic factor (BDNF) expression is induced by fluoxetine. We observed the effects of fluoxetine on a streptozotocin (STZ)-induced diabetic rat model in this study.

Materials and methods: Rats were divided into three groups: Control, diabetic (65 mg/kg STZ injection), and diabetic with fluoxetine injection (20 mg/kg/week, six times). Western blotting was performed using anti-BDNF and anti-hexaribonucleotide-binding protein-3. Expression of BCL2 apoptosis regulator-like protein 11 (BIM) was analysed using a reverse transcription-polymerase chain reaction.

Results: BDNF levels were significantly higher in the diabetic group treated with fluoxetine than in the untreated diabetic group. BIM expression was higher in the diabetic group than in the control group. BIM gene expression was lower in fluoxetine-treated diabetic group than in the untreated diabetic group.

Conclusion: Fluoxetine had an anti-apoptotic effect with upregulation of BDNF expression in retina of rats with STZ-induced diabetes.

Keywords: BDNF; BIM; diabetic; fluoxetine; retina.

MeSH terms

  • Animals
  • Brain-Derived Neurotrophic Factor* / genetics
  • Diabetes Mellitus, Experimental* / drug therapy
  • Diabetes Mellitus, Experimental* / genetics
  • Fluoxetine / pharmacology
  • Rats
  • Retina
  • Streptozocin

Substances

  • Brain-Derived Neurotrophic Factor
  • Fluoxetine
  • Streptozocin